Continued research focusing on blocking inflammation-related mechanisms in cancer, such as the COX-2 / PGE2 pathway and CD147, may help to decrease tumour formation and progression and thus potentially improve the quality of life and survival rates of cancer patients, including those with OSCC. This evidence concerns the gene BSG and neoplasm.